IGF1R and neoplasm: The combination of the anti-IGF1R mAb h7C10 [112] and the mTOR inhibitor rapamycin significanlty inhibited in vivo xenograft tumor growth [186], preventing tumor escape observed after the anti-IGF1R mAb h7C10 treatment alone and limiting the potential problem of mTOR inhibitors-evoked up-regulation of AKT [186].